Published in J Thromb Thrombolysis on October 01, 2007
Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin Pharmacol Ther (2011) 4.42
A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood (2008) 4.02
The largest prospective warfarin-treated cohort supports genetic forecasting. Blood (2008) 2.79
Bioinformatics challenges for personalized medicine. Bioinformatics (2011) 2.28
A new warfarin dosing algorithm including VKORC1 3730 G > A polymorphism: comparison with results obtained by other published algorithms. Eur J Clin Pharmacol (2012) 2.07
Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy. Blood (2008) 1.99
Assessment of the pharmacogenomics educational needs of pharmacists. Am J Pharm Educ (2011) 1.62
Genetic warfarin dosing: tables versus algorithms. J Am Coll Cardiol (2011) 1.43
Extending and evaluating a warfarin dosing algorithm that includes CYP4F2 and pooled rare variants of CYP2C9. Pharmacogenet Genomics (2010) 1.14
Development and evaluation of a pharmacogenomics educational program for pharmacists. Am J Pharm Educ (2013) 1.06
Validation and comparison of pharmacogenetics-based warfarin dosing algorithms for application of pharmacogenetic testing. J Mol Diagn (2010) 1.06
Novel variants of major drug-metabolising enzyme genes in diverse African populations and their predicted functional effects. Hum Genomics (2009) 1.06
Relating human genetic variation to variation in drug responses. Trends Genet (2012) 1.05
VKORC1 pharmacogenomics summary. Pharmacogenet Genomics (2010) 0.94
Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol. Ann Oncol (2016) 0.93
Chapter 11: challenges in and principles for conducting systematic reviews of genetic tests used as predictive indicators. J Gen Intern Med (2012) 0.90
Warfarin dosage response related pharmacogenetics in Chinese population. PLoS One (2015) 0.90
Pharmacogenetics education in British medical schools. Genomic Med (2009) 0.88
Pharmacogenomics discovery and implementation in genome-wide association studies era. Wiley Interdiscip Rev Syst Biol Med (2012) 0.88
Pathway analysis of genome-wide data improves warfarin dose prediction. BMC Genomics (2013) 0.87
Warfarin anticoagulant therapy: a Southern Italy pharmacogenetics-based dosing model. PLoS One (2013) 0.87
Influence of genetic, biological and pharmacological factors on warfarin dose in a Southern Brazilian population of European ancestry. Br J Clin Pharmacol (2011) 0.87
Pharmacogenetic testing and therapeutic drug monitoring are complementary tools for optimal individualization of drug therapy. Eur J Clin Pharmacol (2010) 0.86
Role of pharmacogenomics in drug discovery and development. Indian J Pharmacol (2008) 0.84
Inter and intra ethnic variation of vitamin K epoxide reductase complex and cytochrome P450 4F2 genetic polymorphisms and their prevalence in South Indian population. Indian J Hum Genet (2013) 0.84
Genomic architecture of pharmacological efficacy and adverse events. Pharmacogenomics (2014) 0.83
Evaluation of risk factors in patients with vitamin K-dependent coagulopathy presumed to be caused by exposure to brodifacoum. Korean J Intern Med (2014) 0.83
Only connect: personal genomics and the future of American medicine. Mol Diagn Ther (2010) 0.82
Warfarin toxicity and individual variability-clinical case. Toxins (Basel) (2010) 0.82
Prevalence of combinatorial CYP2C9 and VKORC1 genotypes in Puerto Ricans: implications for warfarin management in Hispanics. Ethn Dis (2009) 0.81
Pharmacogenomics of anti-platelet and anti-coagulation therapy. Curr Cardiol Rep (2013) 0.81
Genomics: risk and outcomes in cardiac surgery. Anesthesiol Clin (2008) 0.81
Warfarin pharmacogenomics. P T (2009) 0.81
Personalization of the immunosuppressive treatment in renal transplant recipients: the great challenge in "omics" medicine. Int J Mol Sci (2015) 0.80
Pharmacogenomic trial design: use of a PK/PD model to explore warfarin dosing interventions through clinical trial simulation. Pharmacogenet Genomics (2009) 0.79
A cardiovascular phenotype in warfarin-resistant Vkorc1 mutant rats. Artery Res (2008) 0.79
Impact of polymorphisms of the GGCX gene on maintenance warfarin dose in Chinese populations: Systematic review and meta-analysis. Meta Gene (2015) 0.78
Characteristics of ambulatory anticoagulant adverse drug events: a descriptive study. Thromb J (2010) 0.78
The use of warfarin for DVT prophylaxis following hip and knee arthroplasty: how often are patients within their target INR range? J Arthroplasty (2014) 0.77
Personalizing health care--is this the right time for warfarin? J Gen Intern Med (2009) 0.77
Effect of CYP2C9, VKORC1, and CYP4F2 polymorphisms on warfarin maintenance dose in children aged less than 18 years: a protocol for systematic review and meta-analysis. Syst Rev (2016) 0.77
Frequency distribution of polymorphisms of CYP2C19, CYP2C9, VKORC1 and SLCO1B1 genes in the Yakut population. Res Pharm Sci (2016) 0.77
Impact of genetic variation on perioperative bleeding. Am J Hematol (2008) 0.76
Serious bleeding events due to warfarin and antibiotic co-prescription in a cohort of veterans. Am J Med (2014) 0.76
Analysis of pharmacogenomic variants associated with population differentiation. PLoS One (2015) 0.75
An Assessment of Osteoporotic Conditions among Users and Non-Users of Warfarin: A Case-Control Study. J Clin Diagn Res (2017) 0.75
Rapid genotyping of single nucleotide polymorphisms influencing warfarin drug response by surface-enhanced laser desorption and ionization time-of-flight (SELDI-TOF) mass spectrometry. J Mol Diagn (2010) 0.75
Drug-gene interactions: inherent variability in drug maintenance dose requirements. P T (2014) 0.75
Genetic variation and haplotype structure of the gene Vitamin K epoxide reductase complex, subunit 1 in the Tamilian population. J Pharmacol Pharmacother (2013) 0.75
Effect of gene polymorphims on the warfarin treatment at initial stage. Pharmacogenomics J (2015) 0.75
Personalized healthcare in clotting disorders. Per Med (2010) 0.75
The Active Metabolite of Warfarin (3'-Hydroxywarfarin) and Correlation with INR, Warfarin and Drug Weekly Dosage in Patients under Oral Anticoagulant Therapy: A Pharmacogenetics Study. PLoS One (2016) 0.75
Impact of pharmacometric analyses on new drug approval and labelling decisions: a review of 198 submissions between 2000 and 2008. Clin Pharmacokinet (2011) 2.67
Pharmacogenomic biomarker information in drug labels approved by the United States food and drug administration: prevalence of related drug use. Pharmacotherapy (2008) 2.34
New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process. J Clin Pharmacol (2008) 2.23
Leveraging prior quantitative knowledge to guide drug development decisions and regulatory science recommendations: impact of FDA pharmacometrics during 2004-2006. J Clin Pharmacol (2008) 2.22
Biopharmaceutics classification system: the scientific basis for biowaiver extensions. Pharm Res (2002) 1.74
Medical applications of microarray technologies: a regulatory science perspective. Nat Genet (2002) 1.67
Pharmacogenetics--tailoring treatment for the outliers. N Engl J Med (2009) 1.50
Personalized medicine and genomics: challenges and opportunities in assessing effectiveness, cost-effectiveness, and future research priorities. Med Decis Making (2010) 1.45
Summary workshop report: biopharmaceutics classification system--implementation challenges and extension opportunities. J Pharm Sci (2004) 1.43
Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation. J Natl Cancer Inst (2010) 1.30
Effect of St John's wort on the pharmacokinetics of fexofenadine. Clin Pharmacol Ther (2002) 1.28
Integration and use of biomarkers in drug development, regulation and clinical practice: a US regulatory perspective. Biomark Med (2008) 1.20
Scientific perspectives on drug transporters and their role in drug interactions. Mol Pharm (2006) 1.11
A regulatory science perspective on warfarin therapy: a pharmacogenetic opportunity. J Clin Pharmacol (2009) 1.10
Microarray data--the US FDA, industry and academia. Nat Biotechnol (2003) 1.04
Utility of a physiologically-based pharmacokinetic (PBPK) modeling approach to quantitatively predict a complex drug-drug-disease interaction scenario for rivaroxaban during the drug review process: implications for clinical practice. Biopharm Drug Dispos (2012) 1.04
Quantitative disease, drug, and trial models. Annu Rev Pharmacol Toxicol (2009) 1.04
Evaluation of exposure change of nonrenally eliminated drugs in patients with chronic kidney disease using physiologically based pharmacokinetic modeling and simulation. J Clin Pharmacol (2012) 1.01
Drug-drug, drug-dietary supplement, and drug-citrus fruit and other food interactions: what have we learned? J Clin Pharmacol (2004) 0.95
Clinical pharmacology as a cornerstone of orphan drug development. Nat Rev Drug Discov (2011) 0.94
Pharmacogenomic data: FDA voluntary and required submission guidance. Pharmacogenomics (2004) 0.92
Use of biomarkers from drug discovery through clinical practice: report of the Ninth European Federation of Pharmaceutical Sciences Conference on Optimizing Drug Development. Clin Pharmacol Ther (2003) 0.91
Food and oral antineoplastics: more than meets the eye. Clin Cancer Res (2010) 0.91
Pharmacogenomics in Drug Development and Regulatory Decision-making: the Genomic Data Submission (GDS) Proposal. Pharmacogenomics (2004) 0.90
Qualification of biomarkers for drug development in organ transplantation. Am J Transplant (2007) 0.90
Regulatory perspectives on designing pharmacokinetic studies and optimizing labeling recommendations for patients with chronic kidney disease. J Clin Pharmacol (2012) 0.86
Clinical pharmacokinetics and pharmacodynamics of clopidogrel. Clin Pharmacokinet (2015) 0.86
Regulatory acceptance of toxicogenomics data. Environ Health Perspect (2004) 0.85
Successes achieved and challenges ahead in translating biomarkers into clinical applications. AAPS J (2010) 0.84
Pharmacogenetic research in partnership with American Indian and Alaska Native communities. Pharmacogenomics (2014) 0.83
The Creating an Optimal Warfarin Nomogram (CROWN) Study. Thromb Haemost (2011) 0.82
Learning from product labels and label changes: how to build pharmacogenomics into drug-development programs. Pharmacogenomics (2010) 0.82
4th US FDA-Drug Information Association pharmacogenomics workshop, held 10-12 December, 2007. Pharmacogenomics (2009) 0.81
Understanding the genetic basis for adverse drug effects: the calcineurin inhibitors. Pharmacotherapy (2010) 0.79
Application of pharmacogenomics in clinical pharmacology. Toxicol Mech Methods (2006) 0.78
Clinical Practice Recommendations on Genetic Testing of CYP2C9 and VKORC1 Variants in Warfarin Therapy. Ther Drug Monit (2015) 0.77
Fit-for-purpose pharmacogenomic biomarkers in drug development: a project team case study with 'what-ifs'. Pharmacogenomics (2009) 0.77
Evaluation of hepatic impairment dosing recommendations in FDA-approved product labels. J Clin Pharmacol (2013) 0.75
Variability in cimetidine absorption and plasma double peaks following oral administration in the fasted state in humans: correlation with antral gastric motility. Eur J Pharm Biopharm (2002) 0.75